In the April–June 2018 edition of Corporate Disputes, Dr. Gregory K. Bell discusses recent litigation involving companies operating in the pharmaceutical and medical device sector and the factors driving them. In this roundtable discussion, the panel experts explain the main issues and challenges these types of companies face during the litigation process. To read the article, click the download button to the right.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...